ERBB2 and neoplasm: For the MCF7-HER2 cell line, which was 37% more sensitive to pazopanib in vitro, an inhibition of tumor growth at the highest drug dose was observed 9 days after starting treatment (p = 0.042 (this p value represents a strong trend)); both doses were inhibitory 4 days later with 45% and 47% tumor growth inhibition at 30 and 100 mg/kg, respectively (p = 0.019 (this p value represents a strong trend) p = 0.008, respectively).